Experience of treating COVID-19 with hydroxychloroquine and azithromycin: New Delhi, India

ABSTRACT

The treatment of COVID-19 has been a source of intense controversy in the past. A variety of clinical trials and retrospective studies have shown mixed findings about the effectiveness of certain repurposed medications proposed to treat COVID-19, highlighting the need for further testing.The aim of this research was to add to the current literature some data on the effectiveness and protection of hydroxychloroquine (HCQ) and azithromycin (AZ) as COVID-19 treatment drugs.The results of a traditional therapy (CT) incorporating HCQ and AZ used in the Democratic Republic of India are recorded in this empirical analysis. We contrasted epidemiological and clinical evidence from 1100 (89%) respondents who received the CT and 135 (11%) who did not obtain the TC. At the start of therapy, survival analyses such as Kaplan-Meier and Cox regression were used to assess health success at day 10 and the probability of survival at day 15.On D10, the clinical result in the TC population is significantly higher than in the reference group (p-0.001). The observed side effects are mild and similar in both categories (3 percent vs. 3 percent). Conclusion: This tentative retrospective analysis shows that traditional medicine has a positive and healthy impact in our region, justifying the protocol's continuity at this period. To improve the power of measurements, broader empirical studies with more rigorous assessment parameters are needed.